Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical...
News
LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
Companies to explore collaboration opportunities within LEXEO’s preclinical cardiovascular pipelineNEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO),...
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first half of 2025NEW YORK, Aug....
Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss Second Quarter Fiscal Year 2023 Financial Results
CARLSBAD, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations...
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204...
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced...
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated...
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for...
CLS Americas and Focalyx Co-Marketing Agreement for Image-Guided Focal Laser Ablation of Prostate Tumors Using TRANBERG and Focalyx Fusion Systems
Minimally Invasive, Outpatient Treatment Designed for Quick Recovery and Low Risk of Unwanted ED and UI Side EffectsIRVINE, Calif. and...
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that...
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition...
CloudMD Reports Second Quarter 2023 CloudMD Continues to Drive Execution with Adjusted EBITDA Approaching Breakeven
Adjusted EBITDA1 loss of $0.7 million. This was CloudMD’s third consecutive quarter of improving Adjusted EBITDA, representing a $2.5 million...
Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies...
Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023
VIENNA, Austria, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders,...
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of...
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services
Sales Organization Enhanced, Platform Organization CreatedFREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell...